(Q47998345)

English

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

scientific article published on 19 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

1 reference

ChEBI release 2020-05-28

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

S Macha

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

P Rose

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

M Mattheus

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

R Cinca

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

S Pinnetti

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

U C Broedl

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

H J Woerle

7

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

publication date

19 August 2013

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

16

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

118-123

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

Defining and characterizing the progression of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Glucose handling by the kidney

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12183

21 January 2018

Identifiers

10.1111/DOM.12183

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23859534

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47998345&oldid=2143593880"